[Image caption: AMG0103 targets very specific anatomy (the nucleus pulposus of an intervertebral disc) and very specific physiology: it interferes with inflammatory degeneration of tissues in an intervertebral disc.] A small new study is a big (early) win for a new kind of medication for back pain (and probably more). For now, it’s known as “AMG0103,” a working title for this mouthful of a molecule, which is an NF-kappa B oligonucleotide decoy. Its goal is to suppress inflammation-powe...
